Seeking Alpha
22 Jan 2026, 23:06 UTC · 36w ago
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update
Impact · against what's priced in
HROW faces conflicting drivers as a lowered 2025 revenue guidance of $270M–$280M and a Q3 miss signal short-term headwinds. However, these are offset by strong market share gains for Vevye and Iheezo, with Vevye's preferred formulary status providing a catalyst for 2026 revenue acceleration.
- HROW−0.10
No priced-in read yet
- In context
The lowering of 2025 revenue guidance to $270M–$280M and a slight Q3 miss are negative signals, but the growth in Vevye's formulary status and Iheezo's adoption suggest long-term fundamental strength.
Read from the article alone
Search tags
